AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Evolus Inc. (EOLS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

14.70

-0.18 (-1.21%)

At close: Feb 20, 2025, 3:59 PM

14.62

-0.54%

After-hours: Feb 20, 2025, 06:01 PM EST

undefined% (undefined)

Bid	14.45
Market Cap	930.83M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.91
PE Ratio (ttm)	-16.15
Forward PE	n/a
Analyst	Buy

Ask	14.99
Volume	331,524
Avg. Volume (20D)	742,733
Open	14.85
Previous Close	14.88
Day's Range	14.63 - 15.02
52-Week Range	9.25 - 17.82
Beta	undefined

About EOLS

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California....

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Feb 8, 2018

Employees 322

Stock Exchange NASDAQ

Ticker Symbol EOLS

Website https://www.evolus.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for EOLS stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 56.46% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Evolus Inc. is scheduled to release its earnings on Mar 4, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+5.47%

Evolus shares are trading higher after the company... Unlock content with Pro Subscription

1 month ago

+28.26%

Evolus shares are trading higher after the company announced it expects FDA approval for Evolysse gels within 90 days and is eyeing a Q2 2025 rollout in the US. Additionally, the company reported Q4 and FY24 revenue results and provided FY25 guidance.

News

17 hours ago · businesswire.com

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team w...

2 days ago · businesswire.com

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...

6 days ago · zacks.com

Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last?

Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

1 week ago · reuters.com

US FDA approves Evolus' anti-wrinkle gels

Evolus said on Thursday the U.S. Food and Drug Administration has approved its two new anti-wrinkle injectable gels, expanding the company's product portfolio beyond its cosmetic injection Jeuveau.

1 week ago · businesswire.com

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administr...

1 week ago · businesswire.com

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qu...

4 weeks ago · zacks.com

Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?

Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

1 month ago · businesswire.com

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net...

1 month ago · seekingalpha.com

Evolus: Still Bullish, But Business Faces Tricky Challenges In '25

I previously rated Evolus, Inc. stock a “Buy” due to its litigation settlement with AbbVie, strong revenue targets, and promising product performance. Despite positive updates, Evolus stock fell sharp...